Direct RNA sequencing and early evolution of SARS-CoV-2

George Taiaroa[1,2], Daniel Rawlinson[1], Leo Featherstone[1], Miranda Pitt[1], Leon Caly[2], Julian Druce[2], Damian Purcell[1], Leigh Harty[1], Thomas Tran[2], Jason Roberts[2], Nichollas Scott[1], Mike Catton[2], Deborah Williamson[1,3], Lachlan Coin[1·], Sebastian Duchene[1·]

1. Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
2. Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.
3. Department of Microbiology, Royal Melbourne Hospital, Victoria, Australia
- These authors contributed equally to the work

Corresponding author:

George Taiaroa, The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia Tel: +61 (0)3 8344 5466. Email: george.taiaroa@unimelb.edu.au

Abstract - Fundamental aspects of SARS-CoV-2 biology remain to be described, having the potential to provide insight to the response effort for this high-priority pathogen. Here we describe the first native RNA sequence of SARS-CoV-2, detailing the coronaviral transcriptome and epitranscriptome, and share these data publicly. A data-driven inference of viral genetic features and evolutionary rate is also made. The rapid sharing of sequence information throughout the SARS-CoV-2 pandemic represents an inflection point for public health and genomic epidemiology, providing early insights into the biology and evolution of this emerging pathogen.

The pandemic of severe acute respiratory syndrome 2 (SARS-CoV-2), causing the disease COVID-19 and originating in Wuhan, China, has spread to more than 200 countries and territories, and has caused more than 1,000,000 cases globally [1-4]. SARS-CoV-2 is a positive-sense single-stranded RNA ((+)ssRNA) virus, belonging to the *Coronaviridae* family and *betacoronavirus* genus [5]. Related betacoronaviruses are capable of infection and

ongoing transmission in mammalian and avian hosts, resulting in illness in humans such as

Middle East respiratory syndrome (MERS) and the original severe acute respiratory

syndrome (SARS) as examples [6-7]. Based on the limited sampling of potential reservoir

species, SARS-CoV-2 has been found to be most similar to bat betacoronaviruses on a

genomic level, potentially indicating that bats are a natural reservoir [5,8].

The genome sequence of SARS-CoV-2 was rapidly determined and shared on January 5th

of 2020, being 29,903 nucleotides in length, and annotated based on sequence similarity to

other coronaviruses (GenBank: MN908947.3). As the emergence of SARS-CoV-2 has

escalated, genomic analyses have played a key role in public health responses, including in

the design of appropriate molecular diagnostics and supporting epidemiological efforts to

track and contain the outbreak [9,10]. Taken together, publicly available sequence data

suggest a recently occurring, point-source outbreak, as described in online sources [10-12].

Aspects of the response assume that the biology of SARS-CoV-2 is comparable with

previously characterised coronaviruses, including the annotation of genes and the estimation

of molecular evolutionary rates [11-12]. It remains highly relevant to determine these

features experimentally with SARS-CoV-2-specific data, potentially revealing other insights

into the biology of this emergent pathogen. To address this, here we describe (i) the first

native RNA sequence of SARS-CoV-2, detailing the coronaviral transcriptome and

epitranscriptome, and (ii) estimates of coronaviral evolutionary rates and related timescales,

based on data available at this stage of the outbreak.

Characterised coronaviruses have some of the largest genomes among RNA viruses, and

express their genetic content as a nested set of polyadenylated mRNA transcripts (Figure 1),

with lengths corresponding to each encoded open reading frame (ORF). These include two

large ORFs, ORF1a and ORF1ab, encoded by the complete viral genome and expressed

upon cell entry. Other subgenomic mRNAs are generated through a mechanism termed

discontinuous extension of minus strands, encoding structural proteins (spike protein (S),

envelope protein (E), membrane protein (M) and nucleocapsid protein (N)) and accessory

proteins (3a, 6, 7a, 7b, 8 and 10). The subgenomic mRNAs have a common 5′ leader

sequence, near-identical to that located in the 5′-UTR of the viral genome; the transcription

mechanism repositions the 5′ leader sequence upstream of ORFs, with each translation

start site being located at the primary position for ribosome scanning. These ORFs, although

annotated, are yet to be shown as expressed experimentally. Standard sequencing

technologies are unable to produce reads representing (i) complete RNA viral genomes or

(ii) subgenomic mRNAs needed to verify annotated ORFs, as these methods generate short

reads and have a reliance on amplification to generate complementary DNA (cDNA)

sequences.

To define the architecture of the coronaviral transcriptome, a recently established direct RNA

sequencing approach was applied, using a highly parallel array of nanopores [16]. In brief,

nucleic acids were prepared from cell culture material with high levels of SARS-CoV-2

growth, this being expected to include examples of both genomic mRNA and transcripts

corresponding to each ORF. These were sequenced with Oxford Nanopore Technologies,

including poly(T) adaptors and an R9.4 flowcell on a GridION platform (Oxford Nanopore

Technologies). Through this approach, the electronic current is measured as individual

strands of RNA translocate through a nanopore, with derived signal-space data basecalled

to infer the corresponding nucleobases. As a comparator, virion material of SARS-CoV-2

was also prepared and sequenced through this approach, with complete viral genome

sequences expected to predominate rather than subgenomic transcripts.

The cellular-derived material was used to generate 680,347 reads, comprising 860Mb of

sequence information (BioProject PRJNA608224). Aligning to the genome of the cultured

SARS-CoV-2 isolate (MT007544.1), a subset of reads were attributed to coronavirus

sequences (28.9%), comprising 367Mb of sequence distributed across the 29,893 base

genome. Of these, a number had lengths >20,000 bases, capturing the majority of the

SARS-CoV-2 genome on a single molecule. This direct RNA sequencing approach

generated an average 12,230 fold coverage of the coronaviral genome, biased towards

sequences proximal to the polyadenylated 3' tail; coverage ranged from 34 fold to >160,000

fold (Figure 1B), reflecting the higher abundance of subgenomic mRNAs carrying these

sequences, as well as the directional sequencing from the polyadenylated 3' tail. The virion

material generated fewer reads, and included a calibration standard added during library

preparation (430,923 reads, BioProject PRJNA608224).

Many features of SARS-CoV-2 biology are captured in these direct RNA sequence data,

including the transcriptome, as well as RNA base modifications or 'epitranscriptome'. To

define the transcriptome, the shared 5' leader sequence was used as a marker to identify

intact transcripts, these corresponding to subgenomic mRNAs and having a low abundance

in the virion-derived data (Supplementary Figures 1 and 2). In SARS-CoV-2, we identify

eight major viral mRNAs in addition to the viral genome; each annotated gene was observed

as a distinct subgenomic mRNA, outside of ORF7b and ORF10 (Figure 1C, Supplementary

Table 1). In SARS, ORF7a and ORF7b are encoded on a shared subgenomic mRNA, with

translation of ORF7b being achieved through ribosome leaky scanning, explaining the

absence of a dedicated ORF7b-encoding subgenomic mRNA [17]. There is however no

satisfactory explanation for the absence of an ORF10-encoding subgenomic mRNA.

ORF10 is the last predicted coding sequence upstream of the poly-A sequence, and the

shortest of the predicted coding sequences at 117 bases in length. ORF10 also has no

annotated function, and the putative encoded peptide does not appear in SARS-CoV-2

proteomes [18,19] or have a homolog in the SARS-CoV-1 proteome (Proteome ID:

UP000000354 [20]). Subgenomic mRNAs corresponding to ORF10 are not identifiable in our

reads (Supplementary Figure 3). These data suggest that the sequence currently annotated

as ORF10 does not have a protein coding function in SARS-CoV-2. Ongoing molecular

evolution at this locus should be considered in light of this finding.

Instead of encoding a protein sequence, the locus annotated as ORF10 immediately

upstream of the 3' UTR may act itself or as a precursor of other RNAs in the regulation of

gene expression, replication or modulating translation efficiency or cellular antiviral

pathways; the 3' UTR of coronaviruses contains domains critical for regulating viral RNA

synthesis and other aspects of viral biology [21]. An initial region of the 3' UTR appears

essential for viral replication, and an area further 3' includes the stem-loop II-like motif (s2m)

a feature conserved in SARS-CoV-2 and other coronaviruses [22,23], the s2m having a

proposed role in recruiting host translational machinery [24]. A small number of cell culture-

derived SARS-CoV-2 genomes carry a shared deletion at an area of the 3' UTR including an

aspect of the s2m (Supplementary Figure 4), this parallel molecular evolution further

suggesting the region may have functional roles *in vivo*.

An analysis of transcript breakpoints further illustrates the potential for 5' UTR positions

outside of the canonical leader sequence to enable transcript production, with low-frequency

non-canonical variations in mRNA splice co-ordinates (Figure 2, Supplementary Figures 5

and 6). Low frequency variants may be generated during the preparation of nucleic acids for

sequencing, with the rate of chimeric read formation being unknown; this could be explored

through analysis of *in vitro* transcribed RNA control material.

In addition to RNA modifications such as the methylation of the 5' cap structure and

polyadenylation of the 3' terminus needed for efficient translation of coding sequences, other

RNA modifications may have functional roles in SARS-CoV-2 [25]. A range of modifications

are identifiable using direct RNA sequence data [16,25]; our available SARS-CoV-2 direct

RNA sequence data providing adequate coverage to confidently call specific modifications.

Through analysis of signal-space data, we identified 42 positions with predicted 5-

methylcytosine modifications, appearing at consistent positions between subgenomic

mRNAs (Supplementary Figure 7, and Supplementary Table 2). In other positive ssRNA

viruses, RNA methylation can change dynamically during the course of infection [26],

influencing host-pathogen interaction and viral replication. Other modifications may become

apparent once training datasets are available for direct RNA sequence data, with little known

of the epitranscriptomic landscape of coronaviruses [25,27].

As well as investigating the above assumed features of SARS-CoV-2 genetics, sequence

data also enable an estimate of the molecular evolutionary rate, with globally sourced

genome sequences being shared and publicly available. Evolutionary rate estimates from

other coronaviruses such as Middle East Respiratory Syndrome (MERS) are not necessarily

applicable here, particularly because MERS had multiple independent introductions into

humans [28-30]. To estimate the evolutionary rate and time of origin of the SARS-CoV-2

outbreak, we carried out Bayesian phylogenetic analyses using a curated set of 122 high

quality publicly available SARS-CoV-2 genome sequences, each having a known collection

date (Figure 3, Supplementary Table 3). The sampling times were sufficient to calibrate a

molecular clock and infer the evolutionary rate and timescale of the outbreak using a

Bayesian approach; the evolutionary rate of SARS-CoV-2 was estimated to be 1.20×10^{-3}

substitutions/site/year (95% HPD 8.91×10^{-4} - 1.52×10^{-3}), and the of time of origin to be late

November 2019 (95% HPD August 2019, December 2019), which is in agreement with

epidemiological evidence and other recent analyses (Figure 3A) [1-4, 31, 32].

A further set of 66 high quality genomes collected earlier in the outbreak (Supplementary

Table 4), and maximal diversity data set from all data available in GISAID to March 28th to

show the utility of capturing varying degrees of genetic diversity (Supplementary Table 5).

This Bayesian approach demonstrated improved precision in estimates of evolutionary rates

using our dataset with highest genetic diversity. This may be explained by the stochastic

variation typical in data from early in an outbreak having a smaller impact as the virus

accumulates genetic variation. These results are also supported by root-to-tip regression, a

visual assessment of the degree of clocklike evolution in the data (Supplementary Figures 8

and 9). The evolutionary rate generated the high diversity set of 100 genomes was $1.56 \times$

10^{-3} substitutions/site/year (95% HPD 1.09×10^{-3} - 2.05×10^{-3}), whereas that based on 66

genomes was 1.16×10^{-3} substitutions/site/year (95% HPD 6.32×10^{-4} - 1.69×10^{-3}). Our

estimate of the evolutionary rate of SARS-CoV-2 is in line with those of other coronaviruses

(Figure 3B), and the low genomic diversity and recent timescale of the outbreak support a

recently occurring, point-source transfer to humans.

Other phylodynamic inferences may soon become possible for SARS-CoV-2, as further

genomic data becomes available and the sampling rate becomes more consistent. The

current distribution of sampling times (Supplementary Figure 8) appears to be prohibitive to

phylodynamic inference of the SARS-CoV-2 effective population size (N_e, not included here).

Although a required threshold of genomes to allow such phylodynamic investigation may

have been crossed, the temporal spread of these isolates may differ too much to satisfy

constant sampling assumptions underlying many phylodynamic skyline approaches inferring

N_e over time. Again, as sampling continues a more consistent rate of sampling is likely to

emerge, allowing such analyses.

Insights are provided on the molecular biology of SARS-CoV-2, revealed through the use of

direct RNA sequence and publicly available data. The rapid sharing of these and other

genetic data support the global response effort and represents an inflection point for

communicable diseases and genomic epidemiology, with complete data shared openly and

rapidly between academic and public health groups.

Figure 1. SARS-CoV-2 genetics and transcriptome architecture.

A) Schematic of the early stages of SARS-CoV-2 cell entry and transcript production, including *in vivo* synthesis of positive sense genome-length RNA molecules and subgenomic mRNAs. B) Read coverage of direct RNA reads from cell-culture material, aligned to the local SARS-CoV-2 genome (29,893 bases), showing a bias towards the 3' polyadenylated end. C) Read length histogram, showing subgenomic mRNAs attributed to coding sequences.

Figure 2. Breakpoint analysis of the SARS-CoV-2 transcriptome.

Direct RNA reads carrying a breakpoint relative to the 5' leader sequence are shown, representing potentially viable transcripts. These breakpoints are localised at the same position on the leader sequence (positions 62-68), and on the 3' to predicted transcription regulating sequences in the body of the genome (TRS-Bs, highlighted by vertical weight lines), generating common subgenomic mRNAs. Of note, many low frequency breakpoints are detected, although few near the sequence currently annotated as ORF10. The key shows the distribution of transcript breakpoints. Colour is matched to a 'value' measuring the number of reads with break points at that position, log10-scaled. The histogram component illustrates the number of transcripts with a given abundance value.

218
219 **Figure 3. Assessment of viral evolutionary rate and outbreak timing with SARS-CoV-2-**
220 **specific data.** A) A timed highest clade-credibility phylogenetic tree of curated SARS-CoV-2
221 genomes as inferred in BEAST. B) Comparison of SARS-CoV-2 rate estimates with varying
222 datasets, and previously published estimates of other coronaviruses.

223 References
224

[1]   World Health Organization. Pneumonia of unknown cause — China. 2020
(https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-
china/en/).

[2]   United Nations Development Programme – March 2020. UNDP support for
coronavirus-affected countries goes beyond health.
https://www.undp.org/content/undp/en/home/blog/2020/undp-support-for-
coronavirus-affected-countries-goes-beyond-heal.html

[3]   Dong, Ensheng, Hongru Du, and Lauren Gardner. "An interactive web-based
dashboard to track COVID-19 in real time." The Lancet Infectious Diseases (2020).
DOI: 10.1016/S1473-3099(20)30120-1

[4]   World Health Organization. Statement on the second meeting of the International
Health Regulations (2005) Emergency Committee regarding the outbreak of novel
coronavirus (2019-nCoV). January 30, 2020 (https://www.who.int/news-
room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-
health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-
coronavirus-(2019-ncov).

[5]   Lu, Roujian, et al. "Genomic characterisation and epidemiology of 2019 novel
coronavirus: implications for virus origins and receptor binding." The Lancet (2020).
DOI: 10.1016/S0140-6736(20)30251-8

[6]   Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome.
New England Journal of Medicine. 2003 Dec 18;349(25):2431-41. DOI:
10.1056/NEJMra032498

[7]   Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif
ZN, Assad M, Almulhim A, Makhdoom H, Madani H. Hospital outbreak of Middle East
respiratory syndrome coronavirus. New England Journal of Medicine. 2013 Aug
1;369(5):407-16. DOI: 10.1056/NEJMoa1306742

[8]   Perlman, S. Another decade, another coronavirus. New England Journal of Medicine.
259   2020 February 20; 382:760-762. DOI: 10.1056/NEJMe2001126
260
261   [9]   Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data–from
262   vision to reality. Eurosurveillance. 2017 Mar 30;22(13). https://www.gisaid.org/
263
264   [10]   Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P,
265   Bedford T, Neher RA. Nextstrain: real-time tracking of pathogen evolution.
266   Bioinformatics. 2018 Dec 1;34(23):4121-3. https://nextstrain.org/ncov
267
268   [11]   Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The Proximal Origin of
269   SARS-CoV-2. Virological, accessed on 27/02/2020. http://virological.org/t/the-
270   proximal-origin-of-sars-cov-2/398
271
272   [12]   Rambaut A. Phylodynamic Analysis | 129 genomes | 24 Feb 2020. Virological,
273   accessed 27/02/2020. http://virological.org/t/phylodynamic-analysis-129-genomes-
274   24-feb-2020/356
275
276   [13]   Yount B, Curtis KM, Fritz EA, Hensley LE, Jahrling PB, Prentice E, Denison MR,
277   Geisbert TW, Baric RS. Reverse genetics with a full-length infectious cDNA of severe
278   acute respiratory syndrome coronavirus. Proceedings of the National Academy of
279   Sciences. 2003 Oct 28;100(22):12995-3000. DOI: 10.1073/pnas.1735582100
280
281   [14]   Brian DA, Baric RS. Coronavirus genome structure and replication. InCoronavirus
282   replication and reverse genetics 2005 (pp. 1-30). Springer, Berlin, Heidelberg.
283
284   [15]   Chen Y, Cai H, Xiang N, Tien P, Ahola T, Guo D. Functional screen reveals SARS
285   coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase.
286   Proceedings of the National Academy of Sciences. 2009 Mar 3;106(9):3484-9. DOI:
287   10.1073/pnas.0808790106
288
289   [16]   Garalde DR, Snell EA, Jachimowicz D, Sipos B, Lloyd JH, Bruce M, Pantic N,
290   Admassu T, James P, Warland A, Jordan M. Highly parallel direct RNA sequencing
291   on an array of nanopores. Nature methods. 2018 Mar;15(3):201. DOI:
292   10.1038/nmeth.4577

[17]   Schaecher SR, Mackenzie JM, Pekosz A (2007). The ORF7b Protein of Severe

Acute Respiratory Syndrome Coronavirus (SARS-CoV) Is Expressed in Virus-

Infected Cells and Incorporated into SARS-CoV Particles. Journal of Virology, 81(2),

718–731. DOI: 10.1128/JVI.01691-06

[18]   Bojkova D, Klann K, Koch B, Widera M, Krause D, Ciesek S, Cinatl J, Münch C

(2020) SARS-CoV-2 infected host cell proteomics reveal potential therapy targets.

DOI: 10.21203/rs.3.rs-17218/v1

[19]   Davidson AD, Williamson MK, Lewis S, Shoemark D, Carroll MW, Heesom K,

Zambon M, Ellis J, Lewis PA, Hiscox JA, Matthews DA (2020) Characterisation of the

transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and

tandem mass spectrometry reveals evidence for a cell passage induced in-frame

deletion in the spike glycoprotein that removes the furin-like cleavage site. DOI:

10.1101/2020.03.22.002204

[20]   He R, Dobie F, Ballantine M, Leeson A, Li Y, Bastien N, Cutts T, Andonov A, Cao J,

Booth TF, Plummer FA, Tyler S, Baker L, Li X (2004) . Analysis of multimerization of

the SARS coronavirus nucleocapsid protein. Biochemical and Biophysical Research

Communications, 316(2), 476–483. DOI: 10.1016/j.bbrc.2004.02.074

[21]   Goebel SJ, Hsue B, Dombrowski TF, Masters PS. Characterization of the RNA

components of a putative molecular switch in the 3' untranslated region of the murine

coronavirus genome. J Virol. 2004 Jan;78(2):669-82. DOI: 10.1128/jvi.78.2.669-

682.2004

[22]   Tengs T, Kristoffersen AB, Bachvaroff TR, Jonassen CM. A mobile genetic element

with unknown function found in distantly related viruses. Virol J. 2013 Apr 25;10:132.

DOI: 10.1186/1743-422X-10-132

[23]   Rangan R, Zheludev IN, Das R. RNA genome conservation and secondary structure

in SARS-CoV-2 and SARS-related viruses. bioRxiv preprint 2020 DOI:

10.1101/2020.03.27.012906.

[24] Robertson MP, Igel H, Baertsch R, Haussler D, Ares M, Scott WG. The Structure of a
Rigorously Conserved RNA Element within the SARS Virus Genome. PLoS Biol.
2005 Jan; 3(1): e5. DOI: 10.1371/journal.pbio.0030005
331

332 [25] Viehweger A, Krautwurst S, Lamkiewicz K, Madhugiri R, Ziebuhr J, Hölzer M, Marz
333   M. Direct RNA nanopore sequencing of full-length coronavirus genomes provides
334   novel insights into structural variants and enables modification analysis. Genome
335   research. 2019 Sep 1;29(9):1545-54. DOI: 10.1101/gr.247064.118
336

337 [26] Lichinchi G, Zhao BS, Wu Y, Lu Z, Qin Y, He C, Rana TM. Dynamics of human and
338   viral RNA methylation during Zika virus infection. Cell host & microbe. 2016 Nov
339   9;20(5):666-73. DOI: 10.1016/j.chom.2016.10.002
340

341 [27] Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS. Coronaviruses: an
342   RNA proofreading machine regulates replication fidelity and diversity. RNA biology.
343   2011 Mar 1;8(2):270-9. DOI: 10.4161/rna.8.2.15013
344

345 [28] Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the
346   SARS coronavirus during the course of the SARS epidemic in China. Science. 2004
347   Mar 12;303(5664):1666-9. DOI: 10.1126/science.1092002
348

349 [29] Dudas G, Carvalho LM, Rambaut A, Bedford T. MERS-CoV spillover at the camel-
350   human interface. Elife. 2018 Jan 16;7:e31257. DOI: 10.7554/eLife.31257
351

352 [30] Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoom HQ, Assiri A, Al-Tawfiq
353   JA, Alhakeem RF, Madani H, AlRabiah FA, Al Hajjar S. Transmission and evolution
354   of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive
355   genomic study. The Lancet. 2013 Dec 14;382(9909):1993-2002. DOI:
356   10.1016/S0140-6736(13)61887-5
357

358 [31] Andersen K. Clock and TMRCA based on 27 genomes. Virological, accessed on
359   27/02/2020. http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347
360

[32] Bedford, T. Phylodynamic estimation of incidence and prevalence of novel
coronavirus (nCoV) infections through time. Virological, accessed on 27/02/2020.

http://virological.org/t/phylodynamic-estimation-of-incidence-and-prevalence-of-novel-
coronavirus-ncov-infections-through-time/391

Acknowledgements

The authors gratefully acknowledge the traditional peoples of the land on which the work

was carried out, the Wurundjeri Woi-wurrung people of the Kulin nation.

The authors also acknowledge the broader staff of the Victorian Infectious Disease

Reference Laboratory (VIDRL), their public health partners, and VIDRL's major funder, the

Victorian Department of Health and Human Services. The authors also thank David

Matthews and Andrew Davidson of the University of Bristol for useful comments on the

generated data, and Allison Hicks of Harvard T. H. Chan School of Public Health, for critical

review of the manuscript. Lastly, the authors gratefully acknowledge the public health and

academic groups contributing to the preparation, release and analysis of SARS-CoV-2

sequence data, including Nextstrain, GISAID and Virological.

Supplementary Figure 1

Native RNA sequence coverage of the SARS-CoV-2 genome for cell-culture and virion-derived material. A) Coverage of the SARS-CoV-2 genome for the cell-culture dataset, for all reads and for those predicted to be intact mRNA transcripts or 'leader reads', showing an abundance of such transcripts. B) Coverage of the SARS-CoV-2 genome for the virion-derived dataset, showing a relative paucity of intact mRNA transcripts.

Supplementary Figure 2

Distribution of native RNA reads between intact transcripts ('leader reads') and other partial

transcripts and genomic sequences. Intact transcripts include the leader sequence at the 5'

and a polyadenylated 3' end (A and E, for cell-culture material and virion material

respectively), while other partial transcripts or genomes either contain a leader sequence

and lack an appropriate 3' sequence (B and F), vice versa (C and D), or lack both a leader

sequence and an expected 3' end.

Supplementary Figure 3

Absence of observed coding potential for ORF10 in SARS-CoV-2. A) Read length

histogram, showing subgenomic mRNAs attributed to coding sequences, with the area

highlighted shown in detail in a second panel. B) Read length histogram, showing read

counts of lengths corresponding to those of the ORF10 subgenomic mRNA (~360 bases), if

present in the dataset. Of the <500 base reads shown, none align to ORF10.

a. Alignment of the SARS-CoV-2 3' UTR for selected isolates

b. Schematic of predicted pseudoknots in the SARS-CoV-2 3' UTR affected by culture-derived deletions

BetaCoV/Wuhan-Hu-1/2019   BetaCoV/Australia/VIC01/2020   BetaCoV/Sydney/2/2020

Supplementary Figure 4

Structured RNAs in the SARS-CoV-2 3' UTR. A) An alignment of SARS-CoV-2 3' UTR

sequences, including the original Wuhan-Hu-1 sourced from Wuhan, China and considered

the reference genome for the outbreak, and two examples of cultured SARS-CoV-2 isolates

exhibiting deletions in a shared 3' UTR region predicted to form a pseudoknot structure. B)

Predicted pseudoknot structure of the SARS-CoV-2 3'UTR affected by the above culture-

derived deletions.

Supplementary Figure 5

Extended breakpoint analysis of the SARS-CoV-2 transcriptome. The genome coordinates
3' of the breakpoint are extended to include potential 3' sequences positioned between 1-
10,001 of the genome. This highlights low frequency breakpoints, increasing in frequency
near the sequence annotated as ORF10 and the 3' end of the genome. The key shows the
distribution of transcript breakpoints. Colour is matched to a 'value' measuring the number of
reads with break points at that position, log10-scaled. The histogram component illustrates
the number of transcripts with a given abundance value.

Supplementary Figure 6

ORF-specific breakpoint analyses. The corresponding breakpoints for each currently

annotated ORF in the SARS-CoV-2 genome are shown (A-I), highlighting a canonical

breakpoint for ORFs with a corresponding subgenome mRNA, and a low frequency of non-

canonical splice sites often centred on a canonical site. Of note, low frequency splice sites

can be seen for an area between ORF 7a and ORF8, likely corresponding to ORF7b (G).

There is an absence of splice sites for ORF in this dataset (I). The key shows the distribution

of transcript breakpoints. Colour is matched to a 'value' measuring the number of reads with

break points at that position, log10-scaled. The histogram component illustrates the number

of transcripts with a given abundance value.

Supplementary Figure 7

Subgenomic mRNA abundance and predicted sites of modification. A) Coverage of relevant

coding sequences achieved by alignment of subgenomic mRNAs to the SARS-CoV-2

genome (log scale). Red lines indicate the first base of each coding sequence from ORF2-

10. B) Schematic of relevant annotated coding sequences. C) Position of predicted m5C

positions in subgenomic mRNAs. Dark blue lines indicate positions predicted to have >90%

base modification; light blue lines indicate positions predicted to have between 50% and

90% base modification.

a.

Australia
Belgium
England
Finland
France
Germany
Japan
Singapore
South Korea
Taiwan
Thailand
USA

China

December 7th 2019   December 26th 2019   January 14th 2020   February 2nd 2020

b.

Coronaviral species/strain

MERS-CoV   SARS-CoV-2   SARS-CoV-1

Supplementary Figure 8

Assessment of SARS-CoV-2 phylogenetics and viral evolutionary rate based on 66 early
genomes made publicly available. A) A timed highest clade-credibility phylogenetic tree of
curated SARS-CoV-2 66 genomes as inferred in BEAST. B) Comparison of the SARS-CoV-
2 rate estimate for the n=66 set and previously published estimates of other coronaviruses.

Supplementary Figure 9

Time-to-most-common-recent-ancestor (TMRCA)and root-to-tip regression of both early and

maximally diverse SARS-CoV-2 genome datasets. A) TMRCA and root-to-tip regression of

122 high quality complete SARS-CoV-2 genomes made available early in the pandemic.

B) TMRCA and root-to-tip regression of 100 maximally diverse SARS-CoV-2 genomes,

selected from the first 700 genomes made publicly available.

Distribution of SARS-CoV-2 sampling times

Supplementary Figure 10

Distribution of SARS-CoV-2 sampling times used to generate publicly available genomes.

The distribution has notable deviations from an expected exponential growth in the number

of genomes available, such as in mid-February, with constant sampling being an underlying

assumption for many phylodynamic skyline approaches inferring effective population size.

Methods

Samples for direct RNA sequencing

The SARS-CoV-2 material was prepared from the first Australian case of COVID-2019

(Australia/VIC01/2020), maintained in cell culture. In brief, African green monkey kidney

cells expressing the human signalling lymphocytic activation molecule (SLAM; termed

Vero/hSLAM cells accordingly) with associated SARS-CoV-2 infection were grown at 37°C

at 5% CO_2 in media consisting of 10 mL Earle's minimum essential medium, 7% FBS

(Bovogen Biologicals, Keilor East, Aus), 2 mM L-Glutamine, 1 mM Sodium pyruvate, 1500

mg/L sodium bicarbonate, 15 mM HEPES and 0.4 mg/ml geneticin in $25cm^2$ flasks. This

isolate is to the best of our knowledge typical for SARS-CoV-2 isolates, with the genome of

the cultured isolate (MT007544.1) having three single nucleotide variants (T19065C,

T22303G, G26144T) relative to the SARS-CoV-2 Wuhan-Hu-1 reference genome

(MN908947.3), and a 10 base deletion in the 3' UTR. Both the T22303G and 3' UTR

variants have been confirmed as culture-derived through Sanger sequencing of clinical and

culture material, and do not appear in the earlier virion-derived data.

Nucleic acids were prepared from clarified cell-free supernatant (reflecting virion material)

and infected cell culture material (representing actively transcribed and translated viral

material), following inactivation with linear acrylamide and ethanol. RNA was extracted from

100μl of supernatant and a modest pellet for the cell-culture material (~200mg) respectively,

using manually prepared wide-bore pipette tips and minimal steps to maintain RNA length

for long read sequencing, and a QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany).

Carrier RNA was not added to Buffer AVL, with 1% linear acrylamide (Life Technologies,

Carlsbad, CA, USA) added instead. Wash buffer AW1 was omitted from the purification

stage, with RNA eluted in 50 µl of nuclease free water, followed by DNase treatment with

Turbo DNase (Thermo Fisher Scientific, Waltham, MA, USA) 37°C for 30 min. RNA was

cleaned and concentrated to 10 µl using the RNA Clean & Concentrator-5 kit (Zymo

Research, Irvine, CA, USA), as per manufacturer's instructions.

Nanopore sequencing of direct RNA

Prepared RNA (~1μg) was carried into a direct RNA sequence library preparation with the

Oxford Nanopore DRS protocol (SQK- RNA002, Oxford Nanopore Technologies) following

the manufacturer's specifications, with addition of the control RNA in the virion sample.

Libraries were loaded on R9.4 flow cells and sequenced on a GridION device for the cell-

derived material and a MinION device for the virion-derived material (Oxford Nanopore

Technologies), and sequenced for 40 hours. Signal-space data was used to generate

nucleobase sequences ('basecalled') using Guppy, either as a standalone program or as

ont-guppy-for-gridion 3.0.6. Both signal-space and basecalled read data are available at

BioProject PRJNA608224. It should be noted that non-polyadenylated RNAs are not

expected to be detected with this approach.

Characterisation of SARS-CoV-2 transcriptome architecture

Direct RNA reads passing the above given quality thresholds were aligned to the genome of

the cultured Australian SARS-COV-2 isolate (MT007544.1), with parallel and concordant

analyses in Geneious Prime (2019.2.1, [M1]) and minimap2 v 2.11 using the "spliced" preset

[M2]. Coverage statistics were determined from the resulting read alignments. To identify

complete subgenomic mRNAs, reads were aligned to a 62 base SARS-COV-2 leader

sequence (5'ACCUUCCCAGGUAACAAACCAACCAACUUUCGAUCUCUUGUAGAU

CUGUUCUCUAAACGAAC), with reads aligning to the leader sequence being pooled and

visualized in a length histogram. Significant peaks were identified visually and confirmed

with a smoothed z-score algorithm. Reads captured in this binning-by-length strategy were

re-aligned to the reference genome using the above methods and visualized in Tablet [M3].

Subgenome bins were refined to remove reads which did not originate at the 3' poly-A tail as

expected for intact subgenomic mRNAs, or which had leader sequences at least 10bp

longer than expected. Subgenome bins were re-aligned, with coverage calculated in

SAMtools [M4], and plotted using ggplot2 [M5] in R [M6]. Breakpoints in mRNAs were

determined with CIGAR string manipulation; any given spliced region longer than 100bp

(represented by Ns in the CIGAR string after aligning with minimap2) was regarded as a

spliced transcript and the 5' and 3' genome co-ordinates of the breakpoint were recorded for

analysis. The IPKnot webserver [M7] was used to predict the RNA secondary structures,

and the VARNA visualization applet [M8] to produce schematics.

As an alternate method of defining the SARS-CoV-2 transcriptome, reads carrying a

breakpoint relative to the 5' leader sequence are shown, representing potentially viable

transcripts. This was determined through CIGAR string manipulation. Any spliced region

longer than 100bp (represented by Ns in the CIGAR string after aligning with minimap2) was

regarded as a spliced transcript and the 5' and 3' genome co-ordinates of the breakpoint

were recorded for analysis. Locations of Transcription Regulating Sequence in the body of

the genome (TRS-B) were determined with a Position Weight Matrix (PWM) search. Portions

of reads aligning to the conserved TRS in the leader sequence (TRS-L) were transformed

into a count matrix, which was then passed into the FIMO program version 5.5.1 for motif

detection with NRDB as the background distribution [M9]. Detected TRS-B sites are plotted

alongside breakpoint heatmaps.

Data availability

All signal-space (fast5) and basecalled data (fastq) generated in this work are publicly

available on the sequence read archive (SRA), as part of the BioProject PRJNA608224 (See

Supplementary Table 6 for relevant accession numbers).

Identification of 5mC methylation

Nanopore sequencing preserves *in vivo* base modifications and enables their detection from

raw voltage signal information. In brief, the signal-space fast5 files corresponding to

identified subgenomic mRNAs were assessed to identify signal changes corresponding to

5mC methylation. These were first retrieved using the fast5_fetcher_multi function in

SquiggleKit [M10]. Reads were processed to align raw signal with basecalled sequence data

using Tombo v1.5 [https://github.com/nanoporetech/tombo]. Canonical reference sequences

were made for each subgenomic mRNAs, with the binned fast5 files input into the

detect_modifications function, with 5mC as the alternate-model parameter. Outputs were

converted to dampened_fraction wiggle files and exported for visualization and analysis.

Assessment of publicly available proteomes

Proteomic datasets were downloaded from the PRIDE proteomic database [M11] (Pride

accession: PXD017710) and processes using Maxquant (1.6.3.4 [M12]) allowing semi-

specific free-N-terminus tryptic as a protease specificity. Quantitation was set to TMT11 plex

labelling and human proteome (Uniprot: UP000005640) and SARS-CoV2 (build in house)

databases were used. Additional searches were made of the SARS-CoV reference

proteome (Proteome ID: UP000000354), and recently available SARS-CoV-2 proteomic

data [19].

SARS-CoV-2 Phylogenetics

In order to estimate the evolutionary rate and time of origin of SARS-CoV-2, we carried out

phylogenetic analyses in BEAST v1.101 [M13 on three datasets. The first dataset included

66 high quality genomes available up to February 10th 2020, the second consisted of 122

available up to February 24th 2020, both from GISAID and GenBank (Supplementary Table

3). A third maximal diversity dataset (n=100) was included to demonstrate the utility of

capturing varying degrees of genetic diversity, these genomes being selected from the first 700 genomes available on GISAID and maximised phylogenetic diversity achieved using Treemer [M14] (Supplementary Table 4). Temporal signal was assessed using BETS [M15]. Initially we determined whether the evolutionary signal and time over which the genome data were collected was sufficient to calibrate the molecular clock, allowing for the evolutionary rate and timescale of the outbreak to be inferred. The model selection approach from BETS supported a strict molecular clock model with genome sampling times for calibration and a coalescent exponential tree prior, which posits that the number of infected individuals grows exponentially over time. We used the HKY+Γ substitution model, and set the following priors for key parameters:

- A continuous time Markov chain for the evolutionary rate
- A Laplace distribution with mean of 0 and scale of 100 for the growth rate
- An exponential distribution with mean of 1 for the effective population size.

A Markov chain Monte Carlo of length 10^7 was set, sampling every 10^3 steps, and assessed sufficient sampling by verifying that the effective sample size for all parameters was at least 200 as determined in Tracer [M16], automatically discarding 10% of the burn in. We summarised the posterior distribution of phylogenetic trees by selecting the highest clade credibility tree alongside calculating posterior node probabilities and the distribution of node ages. Comparison to other coronaviral evolutionary rates included studies [M17-24].

A root-to-tip regression usually produces lower evolutionary rate estimates than explicit phylogenetic methods [M25], although is commonly used to inspect temporal signal in the data. In our analyses, the data set that maximised phylogenetic diversity had a higher R^2 than that with 122 samples collected earlier, and an evolutionary rate that was more similar to that obtained in BEAST. Although, both data sets had temporal signal according to BETS, the root-to-tip regressions demonstrate that including more genetic diversity can produce improved estimates, probably because stochastic variation has a stronger impact in smaller data sets that are collected early in the outbreak.

[M1]   Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, Thierer T. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012 Jun 15;28(12):1647-9.

600   [M2]   Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018
601   Sep 15;34(18):3094-100.

603   [M3]   Milne I, Bayer M, Stephen G, Cardle L, Marshall D. Tablet: visualizing next-
604   generation sequence assemblies and mappings. Bioinformatics. 2016 (pp. 253-268).
605   Humana Press, New York, NY.

607   [M4]   Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
608   Durbin R. The sequence alignment/map format and SAMtools. Bioinformatics. 2009
609   Aug 15;25(16):2078-9.

611   [M5]   Wickham H. ggplot2: elegant graphics for data analysis. Springer; 2016 Jun 8

613   [M6]   R Core Team (2018). R: A language and environment for statistical computing. R
614   Foundation for Statistical Computing, Vienna, Austria.

616   [M7]   Sato, Kengo, et al. "IPknot: fast and accurate prediction of RNA secondary structures
617   with pseudoknots using integer programming." Bioinformatics. 2011 27.13: i85-i93.

619   [M8]   Darty, Kévin, Alain Denise, and Yann Ponty. "VARNA: Interactive drawing and
620   editing of the RNA secondary structure." Bioinformatics 2009 25.15: 1974.

622   [M9]   Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif.
623   Bioinformatics 2011 27: 1017-1018

625   [M10]   Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, et al. Update of
626   the PRIDE database and its related tools. Nucleic Acids Res. 2016;44(D1):D447-56.

628   [M11]   Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized
629   p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat
630   Biotechnol. 2008;26(12):1367-72. DOI: 10.1038/nbt.1511.

632   [M12]   Ferguson JM, Smith MA. SquiggleKit: A toolkit for manipulating nanopore signal
633   data. Bioinformatics. 2019 Dec 15;35(24):5372-3.

[M13] Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling
trees. BMC evolutionary biology. 2007 Dec;7(1):214.

[M14] Menardo F, Loiseau C, Brites D, Coscolla M, Gygli SM, Rutaihwa LK, Trauner A,
Beisel C, Borrell S, Gagneux S. Treemmer: a tool to reduce large phylogenetic
datasets with minimal loss of diversity. BMC Bioinformatics 2018 19(1), 164. DOI:
10.1186/s12859-018-2164-8

[M15] Duchene S, Stadler T, Ho SY, Duchene DA, Dhanasekaran V, Baele G. Bayesian
Evaluation of Temporal Signal in Measurably Evolving Populations. bioRxiv. 2019
Jan 1:810697.

[M16] Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in
Bayesian phylogenetics using Tracer 1.7. Systematic biology. 2018 Sep;67(5):901.

[M17] Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoom HQ, Assiri A, Al-Tawfiq
JA, Alhakeem RF, Madani H, AlRabiah FA, Al Hajjar S. Transmission and evolution
of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive
genomic study. The Lancet. 2013 Dec 14;382(9909):1993-2002.

[M18] Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah
AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, Albarrak A. Spread, circulation, and
evolution of the Middle East respiratory syndrome coronavirus. MBio. 2014 Feb
28;5(1):e01062-13.

[M19] Dudas G, Carvalho LM, Rambaut A, Bedford T. MERS-CoV spillover at the camel-
human interface. Elife. 2018 Jan 16;7:e31257.

[M20] Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, Boerwinkle E, Fu YX. Moderate
mutation rate in the SARS coronavirus genome and its implications. BMC
evolutionary biology. 2004 Dec 1;4(1):21.

[M21] Salemi M, Fitch WM, Ciccozzi M, Ruiz-Alvarez MJ, Rezza G, Lewis MJ. Severe
acute respiratory syndrome coronavirus sequence characteristics and evolutionary

rate estimate from maximum likelihood analysis. Journal of virology. 2004 Feb

1;78(3):1602-3.

[M22] Wu SF, Du CJ, Wan P, Chen TG, Li JQ, Li D, Zeng YJ, Zhu YP, He FC. The genome

comparison of SARS-CoV and other coronaviruses. Yi chuan= Hereditas. 2003

Jul;25(4):373-82.

[M23] Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the

SARS coronavirus during the course of the SARS epidemic in China. Science. 2004

Mar 12;303(5664):1666-9.

[M24] Sanjuán R. From molecular genetics to phylodynamics: evolutionary relevance of

mutation rates across viruses. PLoS pathogens. 2012 May;8(5).

[M25] Duchêne S, Geoghegan JL, Holmes EC, Ho SY. Estimating evolutionary rates using

time-structured data: a general comparison of phylogenetic methods. Bioinformatics.

2016 32(22), 3375-3379.